Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group

Journal of Clinical Oncology

Volumn 22, Issue 14, 2004, Pages 2909-2917

  Caraceni, Augusto ^a   Zecca, Ernesto ^a   Bonezzi, Cesare ^a   Arcuri, Edoardo ^a   Tur, Ricardo Yaya ^a   Maltoni, Marco ^a   Visentin, Marco ^a   Gorni, Giovanna ^a   Martini, Cinzia ^a   Tirelli, Walter ^a   Barbieri, Massimo ^a   De Conno, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; OPIATE; PLACEBO; 4 AMINOBUTYRIC ACID; ACETIC ACID DERIVATIVE; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ALLODYNIA; ANALGESIA; ARTICLE; CANCER; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSESTHESIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROPATHIC PAIN; OUTCOMES RESEARCH; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; AGED; CANCER INVASION; FEMALE; MALE; METASTASIS; MIDDLE AGED; NERVE COMPRESSION; NERVOUS SYSTEM TUMOR; PAIN; TREATMENT OUTCOME;

ACETIC ACIDS; AGED; AMINES; ANALGESICS; ANALGESICS, OPIOID; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NERVE COMPRESSION SYNDROMES; NERVOUS SYSTEM NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 4344695255     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.141     Document Type: Article

References (41)

1. Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82:263-274, 1999
2. Arner S, Arner B: Differential effect of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand 29:32-36, 1985
3. Cherny NI, Thaler HT, Friedlander-Klar H, et al: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology 44:857-861, 1994
4. Grond S, Radbruch L, Meuser T, et al: Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79:15-20, 1999
5. Agency for Health Care Policy and Research, U. S. Department of Health and Human Services Public Health Service: Management of cancer pain. Clinical practice guideline N. 9, AHCPR Publication N 94-0592. Rockville, MD, 1994
6. Bruera E: Cancer pain: Chronic studies of adjuvants to opiate analgesia, in Max MB, Portenoy RK, Laska EM (eds): Advances in Pain Research and Therapy (vol 18): The design of analgesic clinical trials. New York, Raven Press, 1991, pp 267-281
7. Mercadante S, Arcuri E, Tirelli W, et al: Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study. Tumori 88:239-242, 2002
8. Caraceni A, Zecca E, Martini C, et al: Gabapentin as adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441-445, 1999
9. Chandler A, Williams JE: Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage 20:82-86, 2000
10. Shimoyama M, Shimoyama N, Inturrisi CE, et al: Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain 72:375-382, 1997
11. Partridge B, Chaplan SR, Sakamoto E, et al: Characterization of the effects of Gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 88:196-205, 1998
12. Rose M, Kam P: Gabapentin: Pharmacology and its use in pain management. Anaesthesia 57:451-162, 2002
13. Rowbotham M, Harden N, Stacey B, et al: Gabapentin for the treatment of postherpetic neuralgia. A double blind randomized controlled trial. JAMA 280:1837-1842, 1998
14. Rice ASC, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 94:215-224, 2001
15. Backonja M, Beydoun A, Edwards K, et al: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 280:1831-1836, 1998
16. Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: A randomized, double-blind, placebo-controlled trial. Pain 99:557-566, 2002
17. Bone M, Critchly P, Buggy DJ, et al: Gabapentin in postamputation phantom-limb pain: A randomized, double-blind, placebo-controlled cross-over study. Reg Anesth Pain Med 27:481-486, 2002
18. Eckhardt K, Ammon S, Hofmann U, et al: Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 91:185-191, 2000
19. Dirks J, Fredensborg BB, Christensen D, et al: A randomized study of the effects of single dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 97:537-539, 2002
20. Dirks J, Petersen K, Rowbotham M, et al: Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 97:102-107, 2002
21. Jensen M, Karoly P: Self-report scales and procedures for assessing pain in adults, in Turk D, Melzack R (eds): Handbook of pain assessment. New York, Guilford Press, 2001, pp 15-34
22. Caraceni A, Cherny N, Fainsinger R, et al: Pain measurement tools and methods in clinical research in palliative care: Recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 23:239-255, 2002
23. Galer BS, Jensen MP: Development and preliminary validation of a pain measure specific to neuropathic pain. Neurology 48:332-338, 1997
24. World Health Organization: Handbook for reporting results of cancer treatment. WHO offsett publication n. 48. Geneva, World Health Organization, 1979
25. Frison L, Pocock SJ: Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Stat Med 11:1685-1704, 1992
26. Moher D, Schultz K, Altman D, et al: The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 285:1987-1991, 2001
27. Farrar JT, Portenoy RK, Berlin JA, et al: Defining the clinically important difference in pain outcome measure. Pain 88:287-294, 2000
28. Farrar JT, Young JP, LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149-158, 2001
29. Hanks GWC, Portenoy RK, MacDonald N, et al: Difficult pain problems, in Doyle D, Hanks GW, MacDonald N (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1998, pp 454-487
30. Portenoy RK: Adjuvant analgesics in pain management, in Doyle D, Hanks GWC, MacDonald N (eds): Oxford Textbook of Palliative Medicine (ed 2). Oxford, Oxford University Press, 1998, pp 361-390
31. Tanelian DL, Cousins MJ: Combined neurogenic and nociceptive pain in a patient with Pancoast tumor managed by epidural hydromorphone and oral carbamazepine. Pain 36:85-88, 1989
32. Brose WG, Cousins MJ: Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain 45:145-148, 1991
33. Hardy JR, Rees EAJ, Gwilliam B, et al: A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage 21:204-209, 2001
34. Sloan P, Basta M, Storey P, et al: Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth Analg 89:760-763, 1999
35. Bruera E, Ripamonti C, Brenneis C, et al: A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 7:138-140, 1992
36. Sinnott C: Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manage 23:270-272, 2002
37. Collin E, Poulain P, Gauvain-Piquard A, et al: Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment. Pain 55:319-326, 1993
38. Ellemann K, Sjogren P, Banning AM, et al: Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 5:291-294, 1989
39. Mercadante S, Arcuri E, Tirelli W, et al: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized controlled, double-blind, cross-over, double dose study. J Pain Symptom Manage 20:246-262, 2000
40. Field MJ, Oles RJ, Lewis AS, et al: Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121:1513-1522, 1997
41. Matthews E, Dickerson A: A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 96:633-640, 2002